Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -1.02 is 35% above its 5-year average of -1.57, around the middle of its 5-year range (-3.81–1.85).
70.00% below its 12-month average of -0.60.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.13.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 38 comparable quarters.
FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T16:01:45.528Z. Historical observations retain their original dates. Historical series through 2025-05-12.
EARNINGS PER SHARE (EPS)
-1.02
EARNINGS PER SHARE (EPS) AVG TTM
-0.60
EARNINGS PER SHARE (EPS) AVG 3Y
-1.87
EARNINGS PER SHARE (EPS) AVG 5Y
-1.57
EARNINGS PER SHARE (EPS) AVG 10Y
-2.26
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
-70.00%
CURRENT VS 3Y AVG
+45.53%
CURRENT VS 5Y AVG
+35.24%
CURRENT VS 10Y AVG
+54.96%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Coherus Oncology, Inc.
Market Cap
$164.54M
Earnings Per Share (EPS)
-1.02
TTM Avg
-0.60
3Y Avg
-1.87
5Y Avg
-1.57
Market Cap
$165.58M
Earnings Per Share (EPS)
-2.63
TTM Avg
-1.75
3Y Avg
-1.74
5Y Avg
-1.61
Market Cap
$166.35M
Earnings Per Share (EPS)
0.23
TTM Avg
-0.41
3Y Avg
-0.62
5Y Avg
-0.44
Market Cap
$162.20M
Earnings Per Share (EPS)
-1.50
TTM Avg
-2.49
3Y Avg
-3.17
5Y Avg
-2.41
Market Cap
$169.85M
Earnings Per Share (EPS)
-0.83
TTM Avg
0.02
3Y Avg
0.22
5Y Avg
0.10
Market Cap
$158.63M
Earnings Per Share (EPS)
-28.87
TTM Avg
-17.24
3Y Avg
-11.28
5Y Avg
-9.01
Market Cap
$158.30M
Earnings Per Share (EPS)
-0.90
TTM Avg
-1.19
3Y Avg
-2.61
5Y Avg
-1.83
Market Cap
$171.71M
Earnings Per Share (EPS)
-1.60
TTM Avg
-2.56
3Y Avg
-2.45
5Y Avg
-2.61
Market Cap
$172.75M
Earnings Per Share (EPS)
-27.00
TTM Avg
-15.00
3Y Avg
-27.00
5Y Avg
-32.85
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Coherus Oncology, Inc. (CHRS) | $164.54M | -1.02 | -0.60 | -1.87 | -1.57 |
| Quanterix Corporation (QTRX)vs › | $165.58M | -2.63 | -1.75 | -1.74 | -1.61 |
| OptimizeRx Corp. (OPRX)vs › | $166.35M | 0.23 | -0.41 | -0.62 | -0.44 |
| PepGen Inc. (PEPG)vs › | $162.20M | -1.50 | -2.49 | -3.17 | -2.41 |
| Organogenesis Holdings Inc. (ORGO)vs › | $169.85M | -0.83 | 0.02 | 0.22 | 0.10 |
| Minerva Neurosciences, Inc. (NERV)vs › | $158.63M | -28.87 | -17.24 | -11.28 | -9.01 |
| Inogen, Inc. (INGN)vs › | $158.30M | -0.90 | -1.19 | -2.61 | -1.83 |
| MediWound Ltd. (MDWD)vs › | $171.71M | -1.60 | -2.56 | -2.45 | -2.61 |
| Cue Biopharma, Inc. (CUE)vs › | $172.75M | -27.00 | -15.00 | -27.00 | -32.85 |
| Nkarta, Inc. (NKTX)vs › | $172.78M | -1.57 | -1.50 | -2.00 | -2.13 |
Trailing EPS (TTM)
$-1.02
Forward EPS (Est.)
$-0.89
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -1.45 |
| 2024-12-31 | 0.25 |
| 2023-12-31 | -2.53 |
| 2022-12-31 | -3.76 |
| 2021-12-31 | -3.81 |
| 2020-12-31 | 1.85 |
| 2019-12-31 | 1.29 |
| 2018-12-31 | -3.22 |
| 2017-12-31 | -4.48 |
| 2016-12-31 | -3.04 |
| 2015-12-31 | -6.01 |
| 2014-12-31 | -10.64 |
| 2013-12-31 | -2.97 |
| 2012-12-31 | -11.69 |
